Abstract
The COVID-19 health crisis joined, rather than supplanted, the opioid crisis as the most acutely pressing threats to US public health. In the setting of COVID-19, opioid use disorder treatment paradigms are being disrupted, including the fact that methadone clinics are scrambling to give "take-home"doses where they would typically not. The rapid transition away from in-person examination, dosing and group therapy in an era of social isolation calls for adjustments to clinical practice, including emphasizing patient-provider communication, favoring new inductees on buprenorphine and leveraging technology to optimize safety of medication treatment.
Original language | English (US) |
---|---|
Pages (from-to) | E1-E3 |
Journal | Journal of addiction medicine |
Volume | 14 |
Issue number | 4 |
DOIs | |
State | Published - Jul 1 2020 |
Keywords
- access to care
- buprenorphine
- methadone
- opioid overdose
- public health
ASJC Scopus subject areas
- Psychiatry and Mental health
- Pharmacology (medical)